Stockreport

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERA TM ) technology, targeting op [Read more]